Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (9)
Type
(
1 selected
)
Type
Guidance (311)
Quality standard (30)
Guidance programme
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (16)
Medical technologies guidance (7)
Technology appraisal guidance (284)
Apply filters
Showing 301 to 311 of 311
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Vosoritide for treating achondroplasia in children TSID 12001
Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467
Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902
Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]
Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765
Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477
Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952
Technology appraisal guidance
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments TSID 11915
Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998
Technology appraisal guidance
Zuranolone for treating severe postnatal depression ID6431
Technology appraisal guidance
Previous page
1
…
11
12
Current page
13
Page
13
of
13
Results per page
10
25
50
All
Back to top